The lab is investigating: 1) how the brain regulates torpor and hibernation, 2) how cells and genomes of different organisms adapt to these states, and 3) whether inducing these states can slow down tissue damage, disease progression, and even aging. Funded by the National Institute of General Medical Sciences. In addition to the NIH New Innovator Award, David has been named a Rita Allen Scholar, a Pew-Stewart Cancer Research Scholar, a Janelia Scholar, and a Moore Inventor Fellow. Grant ID: DP2-CA280622. Funded by the National Institute of General Medical Sciences. June 01, 2023 at 08:00 AM EDT. Information on valuation, funding, cap tables, investors, and executives for Eikon Therapeutics. By observing these proteins and their motion under different conditions, he says, its possible to ascertain whether a chemical is having a desired treatment effect. Aartjan (AJ) te Velthuis received his Ph.D. cum laude for his work on the replication of the SARS coronavirus from the University of Leiden, the Netherlands. Dr. Nathavitharana received her BSc in Immunobiology and MD at Imperial College London, and her MPH at Harvard School of Public Health as a UK Kennedy Scholar. Stock Market | FinancialContent Business Page Grant ID: DP2-HD111538. Grant ID: DP2-HL168563. His postdoctoral research in the labs of Drs. Perlmutter estimates that the large funding round means that the company will have enough capital for years before requiring new financing. What are Absorption and Emission Spectrum? This Startup Raised Over $500 Million To Find Better This page last reviewed on February 17, 2023, National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland 20892, U.S. Department of Health and Human Services, U.S. Department of Health & Human Services, Division of Program Coordination, Planning, and Strategic Initiatives (DPCPSI), Advancing Health Communication Science and Practice, Bridge to Artificial Intelligence (Bridge2AI), Community Partnerships to Advance Science for Society (ComPASS), HCS Research Collaboratory (NIH Collaboratory), NIH Director's Early Independence Award (EIA), NIH Director's Transformative Research Awards (TRA), The Human BioMolecular Atlas Program (HuBMAP), Knockout Mouse Phenotyping Program (KOMP2), Molecular Transducers of Physical Activity in Humans (MoTrPAC), Somatic Mosaicism across Human Tissues (SMaHT), Stimulating Peripheral Activity to Relieve Conditions (SPARC), Transformative High Resolution Cryo-Electron Microscopy (CryoEM), Current Common Fund Funding Opportunities, About the Office of Strategic Coordination, A Novel Semi-autonomous Surgeon-in-the-loop in situ Robotic Bioprinting System for Functional and Cosmetic Restoration of, Uncovering Brain-Wide Molecular Determinants of Individual Memory Performance Across Lifespan, Towards a Smart Bionic Eye: AI-Powered Artificial Vision for the Treatment of Incurable Blindness, Synthetic Metabolism to Armor and Enhance a New Class of Cell Therapies, The Inactive X: Discovering Sex Genes that Influence Female Vulnerability to Alzheimer's Disease, New Insights Into the Molecular Regulation of Mechanotransduction, Building a Systematic, Comprehensive Mammalian Cell Fate Map, Understanding Metabolism in Space and Time Mechanistic Analysis of the Dynamic Spatial Organization of Metabolism, Methods to Rapidly Explore Combinatorial Diversity and Their Application to CRISPR-Cas9 Systems, Neuroimmunological Insights Into Brain Development and Dysfunction: An Integrative Approach Focused on Microglial Dynamics, Unraveling the Developmental Logic of Cortical Long-Range Projections Using In Situ Sequencing-Based Neuroanatomy, AI-Assisted Imaging and Prediction of Cardiac Arrhythmia Origins Using 4D Ultrasound, Compliant Limb Reconstruction: Co-engineering Body and Machine to Revolutionize Limb Salvage, Tumor Suppressor Vulnerability Conferred by Aneuploid Loss of Haploinsufficient Metallothionein Genes, Universally-applicable RNA mapping at subcellular and single-base resolution, Unleashing T-Cell Anti-Tumor Response Through Repair of Altered RNA Splicing and Antigen Mimicry Recognition. A self-binding immune complex vaccine elicits strong Such models form the basis for identifying targets for rational drug discovery and phenotypes for unbiased drug screens. Evgeny Kvon is an Assistant Professor in the Department of Developmental and Cell Biology at the University of California, Irvine. Startup Eikon, led by Merck vets, buys three drugs and banks Project Title: Defining mechanisms for natural vision in the primate brain with machine learning At UCSB, Michael leads an interdisciplinary research group focused on the computational modeling of human, animal, computer, and prosthetic vision to elucidate the neuroscience behind bionic technologies that may one day restore useful vision to people living with incurable blindness. January 06, 2022 07:00 AM Eastern Standard Time HAYWARD, Calif.-- ( BUSINESS WIRE )--Eikon Therapeutics, Inc., a pioneer in the application of live-cell He followed this with a post-doc in the lab of Dr. Bernardo Sabatini at Harvard Medical School, where he trained in advanced optical approaches and optogenetics to determine the function of neurotransmitter co-transmission from the acetylcholine-releasing neurons. Copyright 2023 CB Information Services, Inc. All rights reserved. At UC Irvine, the Kvon lab is broadly interested in understanding transcriptional regulation by enhancers during early mammalian development. Dr Areys research program focuses on defining the molecular underpinnings of complex behaviors, which combines her multidisciplinary training in genetics, genomics, molecular and behavioral neuroscience in multiple model systems. From 2016-2019, Maral was a postdoctoral fellow in the research group of Prof. George Whitesides at Harvard University, and Wyss Institute for Biologically Inspired Engineering, working on affordable diagnostic devices to make healthcare and analysis accessible to all. in physics from the Indian Institute of Science, and Ph.D. in physics from Cornell University. New Innovator Award Recipients - National Institutes of Health Grant ID: DP2-HD111537. Grant ID: DP2-MH132943 2013) at UCLA, and bioengineering as a postdoctoral fellow at Stanford University. He completed a postdoctoral fellowship at the University of California, Berkeley, where he was also a Berkeley Institute for Data Science (BIDS) fellow. Grant ID: DP2-NS132373. WebDrug discovery and development company Eikon Therapeutics closed $148 million in Series A financing and appointed Roger Perlmutter CEO. Fleur Ferguson is an Assistant Professor in the Department of Chemistry & Biochemistry and the Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California, San Diego, where she leads an interdisciplinary chemical biology research group. In 2021, AJ moved his lab to Princeton University, where his research focuses on how emerging RNA viruses replicate and induce innate immune responses and disease in humans. Combining this pioneering platform with Rogers leadership and the Eikon team's drug development pedigree puts the company at the very forefront of discovery in the biotech industry., Copyright Gophotonics All Rights Reserved | Eikon is based on a type of microscope technology called "super-resolution microscopy, which allows scientists to study single molecules inside cells. Eikon Therapeutics - Funding, Financials, Valuation By continuing to use this site you are consenting to these choices. Dr. Delaney was recruited to join the Department of Biochemistry and Molecular Biology at the Medical University of South Carolina in 2018, where his laboratory researches the origins and effects of copy-number alterations in cancer. Before his Ph.D., Aaron was a software engineer at the Broad Institute of Harvard and MIT, where he helped to develop software tools for cancer and germline genomics in the labs of Mark DePristo and Gad Getz. Grant ID: DP2-HL168071. WebAbout us Eikon Therapeutics is a new biopharmaceutical company employing revolutionary technology at the interface of biology, engineering and chemistry to discover novel The Sanulli lab at Stanford studies genome organization across length and time scales with the long-term goal to understand how cells leverage the diverse biophysical properties of chromatin to regulate genome functions. News Jan 6, 2022 swfinstitute.org Public Funds Join in Eikon Therapeutics Series B Round News Jan 6, 2022 BioSpace Eikon Boasts Stellar Leadership Lineup and Massive $518 Million Series B News Jan 6, 2022 Eikon Therapeutics Announces $517.8 Million Series B Raise and Expansion of Executive She completed her postdoctoral training with Prof. Alex Schier at Harvard University where she investigated cell diversity and lineage relationships in a developing zebrafish brain. Grant ID: DP2-DK136123. The use of this approach, called liquid biopsies, combined with insights from tumor genome analysis, will be critical to uncover causes of treatment resistance, discover novel genetic biomarkers from the blood, and develop non-invasive applications for cancer precision medicine. She completed her postdoctoral fellowship at the University of Pennsylvania Center for Weight and Eating Disorders and was an Assistant Professor of Psychology in Psychiatry and Surgery at the Perelman School of Medicine. Those drugs are meant to spur anti-tumor activity by targeting certain toll-like receptor proteins. She obtained her PhD at University of California San Francisco, in the lab of Jonathan Weissman, where she pioneered a high-throughput approach to measure RNA structure in cells. There were 20 financings over $100M in Q1: Altos Labs ($3B) Eikon ($518M) Kallyope ($236M) Maze ($190M) We also noted a significant decrease in the number of deals from 2021, including Series A. Her field of expertise is in the investigation of sex differences in Alzheimer's disease (AD) biomarkers in preclinical AD; specifically, her interests lie in what sex biological mechanisms might explain female vulnerability, and resilience, to AD pathology and subsequent cognitive decline.